公开(公告)号：US20230174532A1

公开(公告)日：2023-06-08

申请号：US18162052

申请日：2023-01-31

Applicant: Pfizer Inc.

Inventor： Christopher Ryan BUTLER ,  Michelle Renee GARNSEY ,  Kevin Alexander OGILVIE ,  Jana POLIVKOVA ,  Matthew Forrest SAMMONS ,  Aaron Christopher SMITH ,  Qingyi Yang

IPC: C07D471/20 ,  C07D519/00

CPC classification number: C07D471/20 ,  C07D519/00 ,  C07B2200/13

Abstract: Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:




or their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein. Such conditions, diseases, or disorders include cachexia, anorexia, or anorexia nervosa.

公开(公告)号：US20250084084A1

公开(公告)日：2025-03-13

申请号：US18954736

申请日：2024-11-21

Applicant: Pfizer Inc.

Inventor： Christopher Ryan BUTLER ,  Michelle Renee GARNSEY ,  Kevin Alexander OGILVIE ,  Jana POLIVKOVA ,  Matthew Forrest SAMMONS ,  Aaron Christopher SMITH ,  Qingyi Yang

IPC: C07D471/20 ,  C07D519/00

Abstract: Described herein is a crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one having a powder X-ray diffraction pattern comprising at least one characteristic peak, in terms of 2θ at a copper wavelength, selected from 8.7±0.2, 11.1±0.2, and 13.3±0.2.

公开(公告)号：US20210355117A1

公开(公告)日：2021-11-18

申请号：US16492558

申请日：2018-03-06

Applicant: Pfizer Inc.

Inventor： Michael Aaron BRODNEY ,  Thomas Allen CHAPPIE ,  Jinshan Michael CHEN ,  Jotham Wadsworth COE ,  Karen Jean COFFMAN ,  Paul GALATSIS ,  Michelle Renee GARNSEY ,  Christopher John HELAL ,  Jaclyn Louise Henderson ,  Bethany Lyn KORMOS ,  Ravi G. KURUMBAIL ,  Luis Angel MARTINEZ-ALSINA ,  Martin Youngjin PETTERSSON ,  Matthew Richard REESE ,  Colin Richard ROSE ,  Antonia Friederike STEPAN ,  Patrick Robert VERHOEST ,  Travis T. WAGER ,  Joseph Scott WARMUS ,  Yuan ZHANG

IPC: C07D471/04

Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.